Local Pensions Partnership Investment Ltd boosted its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report) by 10.5% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 42,000 shares of the company’s stock after purchasing an additional 4,000 shares during the quarter. Medpace comprises 0.5% of Local Pensions Partnership Investment Ltd’s holdings, making the stock its 25th largest holding. Local Pensions Partnership Investment Ltd owned 0.15% of Medpace worth $22,265,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other large investors have also added to or reduced their stakes in the company. BOKF NA raised its stake in shares of Medpace by 0.8% during the 3rd quarter. BOKF NA now owns 2,542 shares of the company’s stock worth $1,307,000 after acquiring an additional 20 shares in the last quarter. Valeo Financial Advisors LLC grew its holdings in Medpace by 5.0% in the fourth quarter. Valeo Financial Advisors LLC now owns 444 shares of the company’s stock worth $249,000 after purchasing an additional 21 shares during the last quarter. UMB Bank n.a. increased its position in shares of Medpace by 5.6% during the fourth quarter. UMB Bank n.a. now owns 450 shares of the company’s stock worth $253,000 after purchasing an additional 24 shares in the last quarter. Schulhoff & Co. Inc. lifted its holdings in shares of Medpace by 1.1% during the 4th quarter. Schulhoff & Co. Inc. now owns 2,202 shares of the company’s stock valued at $1,237,000 after purchasing an additional 25 shares during the last quarter. Finally, Balefire LLC boosted its position in shares of Medpace by 6.1% in the 1st quarter. Balefire LLC now owns 451 shares of the company’s stock worth $217,000 after purchasing an additional 26 shares in the last quarter. 77.98% of the stock is currently owned by institutional investors.
Analyst Ratings Changes
Several brokerages recently issued reports on MEDP. BMO Capital Markets upped their target price on Medpace from $400.00 to $600.00 and gave the company a “market perform” rating in a research report on Friday, July 24th. Deutsche Bank Aktiengesellschaft restated a “hold” rating and set a $535.00 price objective on shares of Medpace in a report on Thursday, July 23rd. Mizuho lifted their target price on shares of Medpace from $586.00 to $665.00 and gave the stock an “outperform” rating in a research note on Friday, July 24th. Weiss Ratings upgraded shares of Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday. Finally, Wall Street Zen cut shares of Medpace from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. Three equities research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $584.18.
Medpace Stock Down 0.6%
Medpace stock opened at $578.50 on Friday. Medpace Holdings, Inc. has a 52 week low of $373.00 and a 52 week high of $677.90. The company has a market capitalization of $16.15 billion, a price-to-earnings ratio of 33.91, a price-to-earnings-growth ratio of 2.60 and a beta of 1.15. The stock has a 50-day moving average price of $536.23 and a 200 day moving average price of $492.35.
Medpace (NASDAQ:MEDP – Get Free Report) last issued its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, topping the consensus estimate of $3.98 by $0.27. The company had revenue of $707.33 million for the quarter, compared to the consensus estimate of $689.51 million. Medpace had a net margin of 17.67% and a return on equity of 110.15%. Medpace’s quarterly revenue was up 17.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.10 EPS. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Research analysts anticipate that Medpace Holdings, Inc. will post 17.54 EPS for the current fiscal year.
Insider Buying and Selling
In related news, CEO August J. Troendle sold 17,610 shares of Medpace stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $605.11, for a total transaction of $10,655,987.10. Following the completion of the transaction, the chief executive officer directly owned 615,802 shares in the company, valued at approximately $372,627,948.22. This trade represents a 2.78% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Susan E. Burwig sold 7,500 shares of the business’s stock in a transaction that occurred on Tuesday, July 28th. The shares were sold at an average price of $600.00, for a total value of $4,500,000.00. Following the completion of the transaction, the vice president directly owned 62,984 shares of the company’s stock, valued at $37,790,400. The trade was a 10.64% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 67,195 shares of company stock worth $37,989,998. Corporate insiders own 20.50% of the company’s stock.
Medpace Profile
Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.
Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.
Read More
- Five stocks we like better than Medpace
- Sony and TSMC’s $4.7 Billion Venture Is About More Than Camera Sensors
- Quantum Leaps: Debt-Free as AI Storage Demand Accelerates
- NVIDIA’s $500 Billion GPU Financing Deal Fuels Path Toward $270
- Sandisk’s Margins Look Like Software. Can They Last?
Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report).
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.
